Press Releases July 30, 2026 04:05 PM

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

Relay Therapeutics schedules Q2 2026 financial results and corporate update for August 6, 2026

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
RLAY

Relay Therapeutics announced it will report its second quarter 2026 financial results and corporate highlights on August 6, 2026. The clinical-stage precision medicine company is advancing small molecule therapies targeting cancer and genetic diseases, with a lead asset, zovegalisib, currently in Phase 3 trials for metastatic breast cancer and other indications.

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
RLAY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Relay Therapeutics is focused on small molecule precision medicines for cancer and genetic diseases using its Dynamo® platform.
  • Its lead drug candidate, zovegalisib, is in a pivotal Phase 3 trial for HR+/HER2- metastatic breast cancer and other genetic disease indications.
  • The company has a pipeline that includes treatments for NRAS-driven solid tumors and Fabry disease.

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.

Contact:
Mitch Maisel
[email protected]

Media:
Katie Engleman
1AB
919-333-7722
[email protected]


Risks

  • Clinical development risks including potential failure or delays in Phase 3 trials for zovegalisib, which could impact future revenues.
  • Regulatory approval uncertainties that could delay or prevent commercialization of their drug candidates.
  • Dependence on successful advancement of the pipeline programs, which if unsuccessful, could impact company valuation and investor confidence.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026